Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-100 Phase 2b Study in Major Depressive Disorder
NCT05712187Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing ALTO-100 with Placebo DB (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Week 6. Started Jan 2023; status: completed.
02
Drugs
amdiglurax
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05712187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712187.